Table 1.
The general features of the included RCTs
| First author | Country | Sample size | Age (year) | Regimen | Outcome | Course (moth) |
|---|---|---|---|---|---|---|
| Thobois2013 | France | 19 | 58.6±6.5 | Piribedil 300gm/d+Levodopa 75-300mg/d | Efficacy, UPDRS, HAMD, Side effects | 3 |
| Ziegler2003 | France | 61 | 63.4±7.3 | Piribedil 150gm/d+Levodopa 423 mg/d | Efficacy, UPDRS, Side effects | 6 |
| Tang GW2007 | China | 25 | 58.8±8.9 | Piribedil 150gm/d+Levodopa 125 mg/d | Efficacy, UPDRS | 3 |
| Peng X2014 | China | 29 | 60.6±7.1 | Piribedil 100-150gm/d+Levodopa 500-1000 mg/d | Efficacy, UPDRS, Side effects | 6 |
| Du DQ2013 | China | 21 | Na | Piribedil 100-150gm/d+Levodopa 250-750 mg/d | Efficacy, Side effects | 4 |
| Mao KS2014 | China | 38 | NA | Piribedil 150gm/d+Levodopa 125-1000 mg/d | Efficacy, UPDRS | 4 |
| Wang WF2010 | China | 36 | NA | Piribedil 100gm/d+Levodopa 125-500 mg/d | UPDRS | 6 |
| Cheng YB2007 | China | 20 | 62.8±5.2 | Piribedil 50-100gm/d+Levodopa 150 mg/d | UPDRS, HAMD | 6 |
| Zheng CM2010 | China | 29 | 64.3±7.1 | Piribedil 150-250gm/d+Levodopa 300-600 mg/d | Efficacy, UPDRS | 12 |
| Qian JJ2007 | China | 15 | 63.5±6.0 | Piribedil 50gm/d+Levodopa 250 mg/d | UPDRS | 6 |
| Gong XY2016 | China | 140 | 68.2±2.4 | Piribedil 100-150gm/d+Levodopa 375mg/d | Efficacy, UPDRS | 6 |